Market capitalization | $288.49m |
Enterprise Value | $134.33m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 639.67 |
EV/Sales (TTM) EV/Sales | 1.52 |
P/S ratio (TTM) P/S ratio | 3.26 |
P/B ratio (TTM) P/B ratio | 4.74 |
Revenue growth (TTM) Revenue growth | -43.55% |
Revenue (TTM) Revenue | $88.46m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
4 Analysts have issued a Poseida Therapeutics Inc forecast:
4 Analysts have issued a Poseida Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 88 88 |
44%
44%
|
|
Gross Profit | 83 83 |
45%
45%
|
|
EBITDA | -113 -113 |
383%
383%
|
EBIT (Operating Income) EBIT | -118 -118 |
311%
311%
|
Net Profit | -113 -113 |
286%
286%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Kristin Yarema |
Employees | 330 |
Founded | 2014 |
Website | www.poseida.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.